Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product sales...

Related Keywords

,Neurocrine Biosciences ,Kevin Gorman ,Neurocrine Biosciences Inc ,Sosei Group Corporation ,Linkedin ,Mitsubishi Tanabe Pharma Corporation ,Takeda Pharmaceutical Company ,Nasdaq ,Xenon Pharmaceuticals ,Idorsia Pharmaceuticals ,Chief Executive Officer ,Healthcare Conference ,Fourth Quarter ,Net Product Sales ,Future Milestones ,Supplemental New Drug Application ,Second Half ,Registrational Study ,Top Line Registrational Data ,Line Registrational Data ,Selectivet Type ,Line Phase ,Pediatric Epilepsy ,Adrenal Hyperplasia ,Onset Seizure ,Vesicular Monoamine Transporter ,Calcium Channel ,Epileptic Encephalopathy ,Continuous Spike ,Wave During Sleep ,Corticotropin Releasing Factor Type ,Isoxazole Propionic Acid ,Protein Coupled Receptor ,Sodium Channel ,Bioscience Partners ,East Asia ,Takeda Pharmaceutical Company Limited ,Tardive Dyskinesia ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,